Literature DB >> 11105953

Clinical, hematologic, and immunophenotypic characterization of canine large granular lymphocytosis.

S P McDonough1, P F Moore.   

Abstract

Clinical, hematologic, and immunophenotypic data were studied in 25 dogs with large granular lymphocyte (LGL) lymphocytosis. Primarily large-breed dogs were affected, with an average age at initial diagnosis of 10 years (range 5-14 years). All dogs had persistent (>4 months) LGL lymphocytosis except for three that were euthanized with aggressive disease. Splenomegaly was reported in 12 of 20 dogs in which splenic size was evaluated. The clinical course was heterogeneous and dogs were divided into four groups based on similar clinical and hematologic findings: acute leukemia (3/25), persistent lymphocytosis with anemia (12/25), persistent lymphocytosis without anemia (8/25), and reactive lymphocytosis (2/25). Immunophenotypes varied within groups but were homogeneous among cells from the same patient except in the two dogs classified as reactive LGL lymphocytosis. Analysis of T-cell receptor (TCR) usage identified three main LGL lineages. TCRalphabeta was expressed in 15/25 (60%) cases. TCRgammadelta was expressed in 8/25 (32%) cases, and 2/25 (8%) cases were CD3-, compatible with NK cells. beta2 integrin expression was distinctive. CD11a was consistently expressed, while CD11b was absent. CD11c was expressed only weakly in 16/25 (64%) cases. The leukointegrin alphadbeta2 was highly prevalent on all LGL lineages, being expressed in 23/25 (92%) cases. Prominent involvement of the spleen, relative sparing of bone marrow, an unexpectedly large proportion of gammadelta T-cell LGLs, and the distinctive beta2 integrin expression pattern on diverse lineages of LGLs suggest the disease arises from unique populations of lymphocytes that preferentially localize in the splenic red pulp.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11105953     DOI: 10.1354/vp.37-6-637

Source DB:  PubMed          Journal:  Vet Pathol        ISSN: 0300-9858            Impact factor:   2.221


  9 in total

1.  Large granular intestinal lymphosarcoma and leukemia in a dog.

Authors:  Elisabeth C R Snead
Journal:  Can Vet J       Date:  2007-08       Impact factor: 1.008

2.  Isolation and characterization of canine natural killer cells.

Authors:  Helen T Michael; Daisuke Ito; Valarie McCullar; Bin Zhang; Jeffrey S Miller; Jaime F Modiano
Journal:  Vet Immunol Immunopathol       Date:  2013-06-28       Impact factor: 2.046

3.  Canine T-zone lymphoma: unique immunophenotypic features, outcome, and population characteristics.

Authors:  D M Seelig; P Avery; T Webb; J Yoshimoto; J Bromberek; E J Ehrhart; A C Avery
Journal:  J Vet Intern Med       Date:  2014-03-21       Impact factor: 3.333

4.  Concurrent with T-zone lymphoma and high-grade gastrointestinal cytotoxic T-cell lymphoma in a dog.

Authors:  Akihisa Suwa; Tetsuya Shimoda
Journal:  J Vet Med Sci       Date:  2017-03-12       Impact factor: 1.267

5.  Blastic natural killer cell lymphoma/leukaemia in a cat.

Authors:  Miyuki Hirabayashi; James K Chambers; Mei Sugawara; Aki Ohmi; Hajime Tsujimoto; Hiroyuki Nakayama; Kazuyuki Uchida
Journal:  JFMS Open Rep       Date:  2019-07-11

Review 6.  Flow Cytometry in the Diagnosis of Canine T-Cell Lymphoma.

Authors:  Stefano Comazzi; Fulvio Riondato
Journal:  Front Vet Sci       Date:  2021-04-21

7.  A case of canine renal lymphoma of granular lymphocytes with severe polycythemia.

Authors:  Sara Kotb; Carolina Allende; T William O'Neill; Krista Bruckner; Helio DeMorais; Jana Gordon; Kaitlin Curran; Duncan S Russell; Susanne M Stieger-Vanegas; Jennifer L Johns
Journal:  BMC Vet Res       Date:  2021-04-14       Impact factor: 2.741

8.  Indolent, T-cell, large granular lymphocytic leukaemia in a dog presenting with severe neutropenia and an absence of lymphocytosis.

Authors:  James Elliott; Elizabeth Villiers
Journal:  Open Vet J       Date:  2018-04-01

Review 9.  Characterization and Potential Applications of Dog Natural Killer Cells in Cancer Immunotherapy.

Authors:  Alicia A Gingrich; Jaime F Modiano; Robert J Canter
Journal:  J Clin Med       Date:  2019-10-27       Impact factor: 4.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.